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The parasympathetic limb of the autonomic nervous system regulates the activity 
of multiple organ systems. Muscarinic receptors are G protein coupled receptors 
(GPCRs) that mediate the response to acetylcholine released from 
parasympathetic nerves.  Their role in the unconscious regulation of organ and 
central nervous system function makes them potential therapeutic targets for a 
broad spectrum of diseases. The M2 muscarinic acetylcholine receptor (M2 
receptor) is essential for the physiologic control of cardiovascular function 
through activation of G protein-coupled inwardly-rectifying potassium channels, 
and is of particular interest because of its extensive pharmacological 
characterization with both orthosteric and allosteric ligands. Here we report the 
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structure of antagonist-bound M2 receptor, the first human acetylcholine receptor 
to be characterized structurally. The antagonist QNB binds in the middle of a long 
aqueous channel extending approximately two-thirds through the membrane. 
The orthosteric binding pocket is formed by amino acids that are identical in all 5 
muscarinic receptor subtypes, and shares structural homology with other 
functionally unrelated acetylcholine binding proteins from different species. A 
layer of tyrosine residues forms an aromatic cap restricting dissociation of the 
bound ligand. A binding site for allosteric ligands has been mapped to residues at 
the entrance to the binding pocket near this aromatic cap. The M2 receptor 
structure provides insights into the challenges of developing subtype-selective 
ligands for muscarinic receptors and their propensity for allosteric regulation. 
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The muscarinic receptors constitute a family with five subtypes M1-M51. M1, M3, 
and M5 subtypes couple with the Gq family of G proteins, and M2 and M4 
subtypes with the Gi/Go family of G proteins. The muscarinic acetylcholine 
receptors were originally defined as a functional concept on the basis of the work 
by Dale2 and others showing that the muscarinic action by a series of choline 
esters and other substances in various tissues could be differentiated from their 
nicotinic action.  The muscarinic receptors are now known to be G protein-
coupled receptors (GPCRs)3 and the nicotinic receptor a ligand-gated ion 
channel.  Muscarinic receptors were initially defined biochemically as proteins 
that specifically bound 3-quinuclidinyl-benzilate (QNB) and N-methylscopolamine 
(NMS). They were among the first GPCRs to be purified from cerebral 
membranes4, and to be functionally reconstituted with purified G protein in lipid 
vesicles3.   The M1 receptor5 together with the β2 adrenergic receptor6 were the 
first neurotransmitter-activated GPCRs to be cloned, revealing the seven 
transmembrane segment (TM) topology initially observed for rhodopsin7, and 
subsequently found to be common to all members of the GPCR family.  
 
As a consequence of their roles in both the central and parasympathetic nervous 
systems, muscarinic receptors are targets for treatment of a spectrum of 
disorders including Alzheimer’s disease, schizophrenia and Parkinson’s disease, 
and chronic obstructive pulmonary disease8. However, developing highly subtype 
selective orthosteric drugs for muscarinic receptors has been challenging and 
thus far largely unsuccessful. Recent drug discovery efforts have therefore 
shifted to the development of small molecule allosteric modulators. Muscarinic 
receptors have long been a model system for studying allosteric regulation of 
GPCR signaling because of their exceptional propensity to bind allosteric 
ligands9. To better understand the structural basis for challenges in developing 
orthosteric drugs and the susceptibility for allosteric regulation, we obtained a 
crystal structure of the M2 receptor. 
 
In our initial efforts to obtain the structure of the M2 receptor we expressed and 
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purified M2 receptor lacking most of the third intracellular loop (IL3) and the 
native glycosylation sites. The central part of IL3 of the M2 receptor can be 
removed without impairing its ability to bind to agonists or activate G proteins10, 
and IL3 was shown to have a flexible structure11. Using this modified M2 receptor 
bound to the high affinity inverse agonist R-(–)-3-QNB, we performed 
crystallization by hanging drop vapor diffusion and obtained crystals that 
diffracted to around 9 Å, but were not able to improve the quality of these 
crystals. We subsequently replaced IL3 of the M2 receptor with T4-Lysozyme 
(T4L) as initially described for the β2 adrenergic receptor12 (Supplementary Fig. 
1a). This method has been used to obtain crystal structures of four other GPCRs: 
the adenosine A2A receptor13, the CXCR4 receptor14, the dopamine receptor 
D315, and most recently the histamine H1 receptor16. The binding properties of 
M2-T4L with muscarinic ligands were essentially the same as for the wild type M2 
receptor (Supplementary Fig. 1b,c), indicating that the overall TM architecture of 
M2-T4L was minimally affected by introduction of T4L. The M2-T4L was 
subsequently crystallized in lipidic cubic phase. A 3.0 Å structure was solved by 
molecular replacement from a data set obtained by merging diffraction data from 
23 crystals.  
 
As is typical for proteins crystallized by the lipidic cubic phase method, the lattice 
for the M2 receptor shows alternating aqueous and lipidic layers with M2 receptor 
molecules embedded in the latter while T4L is confined to aqueous regions 
(Supplementary Fig. 2). Within the membrane plane, receptor molecules are 
packed closely against one another, alternating orientations within the bilayer. 
There are abundant hydrophobic contacts between receptor molecules within the 
membrane, while polar interactions primarily involve contacts between T4L 
molecules as well as receptor-T4L interactions.  
 
The overall structure of the M2 receptor (Fig. 1a) is similar to that of rhodopsin 
and other recently crystallized inactive GPCR structures (compared in 
Supplementary Figure 3). The cytoplasmic surface of the M2 receptor is in an 
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inactive conformation, but as with most other GPCR structures, there is no 
interaction involving Arg1213.50 in the conserved E/DRY sequence in TM3 and 
Glu3826.30 in TM6 (Fig. 1b). Instead, the Arg1213.50 side chain forms a salt bridge 
only with Asp1203.49. In rhodopsin, the homologous residues form part of a 
charge-charge interaction that stabilizes the cytoplasmic ends of TM3 and TM6 in 
an inactive state17. The second intracellular loop shows a helical conformation 
similar to that first seen for the turkey β1 adrenergic receptor18. 
 
GPCR crystal structures show the greatest differences in the extracellular surface 
(Supplementary Fig. 3). The M2 receptor has a relatively simple and open 
extracellular surface (Fig 1c, d) with the longer extracellular loop (ECL) 2 
stabilized by a conserved disulfide with Cys963.25 at the N-terminus of TM3 and 
Cys176 in the middle of ECL2. In addition, the second disulfide bond was 
detected between C413 and C416 in the ECL3. The extracellular surface of the 
M2 receptor most resembles that of the dopamine D3 receptor (Supplementary 
Fig. 3).  
 
Crystal structures of GPCRs reveal a network of hydrogen bonding interactions 
that extend from the binding pocket to the cytoplasmic surface. However, a 
distinctive feature of the M2 receptor is that this network is part of a long, 
continuous aqueous channel extending from the extracellular surface to a depth 
of approximately 33 Å when measured from ECL2 (Fig 1e). This channel 
contains the ligand binding pocket, but extends beyond the ligand and is 
separated from the cytoplasmic surface by a hydrophobic layer formed by three 
amino acids: Leu652.46 in TM2, Leu1144.43 in TM4 and Ile3926.40 in TM6. Each of 
these is absolutely conserved among all five muscarinic subtypes. The 
dimensions of the channel below the QNB binding site are large enough to 
accommodate a long, extended orthosteric ligand.  Supplementary Figure 4 
compares the aqueous channels of other GPCRs.  
 
The ligand QNB binds within a deeply buried pocket defined by side chains of 
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TM3, 4, 5, 6 and 7 (Fig. 2a-c, Supplementary Fig. 5, Supplementary table 3). An 
aromatic cage encloses the amine and forms a lid over the ligand, separating the 
orthosteric site from the extracellular vestibule. Asp1033.32 and Asn4046.52 serve 
to orient the ligand in the largely hydrophobic binding cavity, with Asn4046.52 
forming paired hydrogen bonds with the hydroxyl and carbonyl groups in QNB 
while Asp1033.32 engages in a charge-charge interaction with the amine moiety of 
the ligand (Fig. 2). The transmembrane segment amino acids that form the QNB 
binding pocket are identical in all five muscarinic receptor subtypes 
(Supplementary Table 1), consistent with results of QNB binding experiments on 
M1-M4 receptors, and with site-directed mutagenesis experiments on M119, M220, 
and M321 receptors.  Only Phe181, which extends downward from ECL2 and 
interacts with one of the two phenyl rings on QNB (Fig. 2), differs from all other 
muscarinic receptor subtypes which have leucine in the homologous position. 
The importance of Asp3.32 for both agonist and antagonist binding has been 
demonstrated in mutagenesis and covalent-labeling experiments and modeling 
studies19-22. In contrast, mutation of Asn4046.52 to Ala on M123 and M324 receptors 
was shown to greatly affect binding of QNB but have little effect on binding of or 
activation by acetylcholine. It is possible that Asn4046.52 is hydrogen-bonded with 
ester group of QNB but not of acetylcholine.  
 
The M2 and other muscarinic receptors represent one of four families of 
acetylcholine binding proteins to be structurally characterized thus far. Figure 3a 
shows the orthosteric binding site of the M2 receptor with acetylcholine docked 
with the gauche form of the O-C2-C1-N dihedral angle, which places the choline 
group in the aromatic cage interacting with Asp1033.32, while the carbonyl oxygen 
is tentatively bound to Asn4046.52 (Fig 3a). The natural agonist acetylcholine is 
much smaller than the bulky antagonist QNB. As described in agonist-bound 
structure of the β2 adrenergic receptor, the contraction of ligand binding pocket is 
expected as a result of an inward shift of TM525. This result is consistent with the 
previous mutation studies showing that Thr1875.39 and Thr1905.42 in TM5 (Fig. 2) 
alter binding of most agonists but not of antagonists20. Bulky compounds capable 
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of blocking activation-related contraction of the pocket would be very efficient in 
locking M2 receptor in an inactive conformation as is exemplified here by the 
antagonist QNB. It has been proposed that the conformational change of M2 
receptor upon activation might be accompanied by conformational change of 
acetylcholine from the gauche to trans form of the O-C2-C1-N dihedral angle26. It 
remains to be determined in which pose acetylcholine binds to the M2 receptor or 
to the M2 receptor-G protein complex, and if acetylcholine hydrogen bonds with 
Asn4046.52 or other residues. 
 
In a striking example of convergent evolution, the orthosteric site of M2 receptor 
exhibits many features noted previously as common structural elements in 
unrelated acetylcholine binding proteins27. Like the M2 receptor, a nicotinic 
acetylcholine receptor homologue bound to acetylcholine (Fig. 3b) shows an 
aromatic cage comprised of three tyrosines and a tryptophan, although it notably 
lacks a counterion to the choline group28, whereas in the M2 receptor this role is 
filled by Asp1033.32. A bacterial acetylcholine binding protein ChoX from 
Sinorhizobium meliloti (Fig. 3c) also possesses an aromatic cage, and like M2 
receptor has an aspartate in close proximity to the amine engaging in a charge-
charge interaction29. Also like the M2 receptor, ChoX has an asparagine hydrogen 
bonding to the ligand carbonyl. Like these proteins, the enzyme acetylcholine 
esterase (Fig. 3d) employs an aromatic cage and a carboxylate to bind the 
choline group, while the (thio)acetyl group interacts with a phenylalanine, likely 
through π-π interactions30. Taken together, these structures suggest that an 
aromatic cage and buried carboxylate are likely to be critical elements for 
acetylcholine recognition and binding in general. 
 
There is a growing interest in the development of allosteric ligands for GPCR 
targets.  This is motivated by the ability to develop more subtype-selective drugs 
targeted at less conserved regions of the receptor.  Moreover, allosteric ligands 
modulate the effects of natural hormones and neurotransmitters, and may 
therefore regulate receptor activity in a more physiologic manner. As noted 
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above, the orthosteric binding pocket is highly conserved among all muscarinic 
receptor subtypes. Allosteric regulation of GPCRs was first observed for the M2 
receptor and this receptor has been one of the most extensively characterized 
allosteric model systems9. Figure 4a shows the inner surface of the M2 receptor 
highlighting residues that are not conserved with its closest relative, the M4 
receptor. It can be seen that the orthosteric binding pocket and transmembrane 
core are highly conserved. The greatest diversity is observed in the extracellular 
loops and the extracellular end of TM segments that form the entrance to the 
orthosteric binding pocket. These amino acids represent structural diversity that 
could be exploited for the development of more subtype-selective ligands9. Of 
interest, site-directed mutagenesis and chimeric receptor studies have implicated 
several of these amino acids in the binding of several well-characterized 
allosteric modulators9.  As shown in Fig 4b-d, these residues are located in ECL2 
and N-terminus of TM7 at the entrance to the binding pocket. Trp4227.35, a 
residue implicated in the binding of several allosteric modulators, appears to form 
an edge-to-face π−π interaction with Tyr4036.51, part of the aromatic cage 
surrounding the charged amine of the orthosteric ligand (Fig. 4d). Binding of 
allosteric ligands to this site would be expected to influence the association and 
disassociation rates of orthosteric ligands.    
 
The structure of the M2 receptor provides insights into both orthosteric and 
allosteric regulation of muscarinic receptors. The development of more selective 
drugs for muscarinic receptors will likely require exploitation of the more diverse 
allosteric surface, either as exclusively allosteric ligands or as ligands that 
occupy both orthosteric and allosteric sites. 
 
Methods summary 
Untagged human M2 muscarinic acetylcholine receptor was expressed in Sf9 
cells with the third intracellular loop replaced with T4 lysozyme, then extracted 
with digitonin and sodium cholate and purified by ligand affinity chromatography, 
then exchanged into decyl maltoside buffer. Purified receptor was crystallized by 
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the lipidic cubic phase technique following addition of a stabilizing neopentyl 
glycol detergent. Data collection was performed at Advanced Photon Source 
beamlines 23ID-B and 23ID-D, and the structure solved by molecular 
replacement. Refinement statistics are given in Supplementary Table 2. 
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Figure 1. The M2 receptor (blue ribbon) with bound QNB (orange spheres). a, M2 
receptor in profile. b, Cytoplasmic surface showing conserved DRY residues in 
TM3.  c, Extracellular view into QNB binding pocket. d, Extracellular view with 
solvent-accessible surface rendering shows a funnel-shaped vestibule and a 
nearly buried QNB binding pocket. e, Aqueous channel (green) extending from 
the extracellular surface into the transmembrane core is interrupted by a layer of 
three hydrophobic residues (blue spheres). Well-ordered water molecules are 
shown as red dots. 
  
Figure 2. Binding interactions between the M2 receptor and QNB. 
a, b, Two views of the QNB binding pocket. Amino acids within 4 Å of the ligand 
are shown as light blue sticks, with QNB in orange. Nitrogen and oxygen atoms 
are colored dark blue and red, respectively. Polar interactions are indicated by 
dashed lines. A 2Fo-Fc map is shown in wire at 1.5 σ contour. c, A schematic 
representation of QNB binding interactions is shown. Mutations of amino acids in 
red boxes have been shown to reduce both antagonist and agonist binding by 
more than 10 fold. Mutations of the amino acid in the purple boxes reduce 
antagonist binding affinity by more that 10 fold. Mutations of amino acids in blue 
boxes reduce agonist binding by more than 10 fold. Blue dotted lines indicate 
potential hydrophobic interactions and red lines indicate potential polar 
interactions.  
 
Figure 3. Convergent evolution of acetylcholine binding sites. a, Acetylcholine is 
modeled into the crystal structure of the M2 receptor. b, Acetylcholine binding 
pocket in the crystal structure of the acetylcholine binding protein from the snail 
Aplysia californica (PDB ID: 2XZ5). c, Acetylcholine binding pocket in the 
acetylcholine binding protein ChoX from the gram negative bacterium 
Sinorhizobium meliloti (PDB ID: 2RIN). d, Binding site for thio-acetylcholine in the 




Figure 4. Allosteric binding in the M2 receptor. a, Differences between the M2 and 
M4 receptors are shown as green residues mapped onto the inner surface of the 
M2 receptor (blue), with QNB in orange spheres. The sequence conservation 
within the orthosteric site is apparent, while residues outside show more 
variability. b-d, Mutations that alter allosteric binding are shown with yellow 
carbons, and amino acids involved in QNB binding are shown with blue carbons 
as sticks or spheres.  b, c, Different views of possible allosteric binding sites in 
the M2 receptor. The surface view in c shows the positions of possible allosteric 
binding sites (yellow) lining the path to the QNB binding pocket. d, Trp422 (yellow 
spheres), implicated in binding of allosteric ligands, forms an edge-to-face 









Construction of M2-T4L expression vectors for Sf9 cells 
The coding sequence of the human M2-T4L was designed to have N-linked 
glycosylation sites (Asn2, Asn3, Asn6 and Asn9) mutated to aspartic acid and 
cysteine-less T4 lysozyme (C54T, C97A) residues 2 - 161 inserted into the third 
intracellular loop, replacing M2 residues 218 – 376. This construct was 
synthesized (TAKARA bio Inc.), and cloned into the pFastbac1 Sf9 expression 
vector (Invitrogen) as illustrated in Supplementary Figure 1a. A TAA stop codon 
was placed after the R466 codon, terminating translation. The synthesized M2-
T4L described above was confirmed by sequencing.  
 
Expression and membrane preparation 
Recombinant baculovirus was made from pFastbac1-M2-T4L using the Bac-to-
Bac system (Invitrogen)31. The M2-T4L protein was expressed in baculovirus 
infected Sf9 insect cell as described previously32. Sf9 insect cells were prepared 
at a density of 1.0 × 106 cells/ml and suspended in 5 L of the IPL-41/SF900 II 
complex media or ESF921 insect media. Media containing Sf9 insect cells were 
transferred into the CELLBAG 22 L/O (GE Healthcare) and cultured for 4 days 
with the following culture conditions: 20 rpm, 8.5° of rocking angle, 30% O2, 0.25 
L/min of air flow rate, and 27°C. After 4 days, 200~300 ml of the M2-T4L 
baculovirus stock (approximate multiplicity of infection (M.O.I) = 2) and 700~800 
ml of IPL-41/SF900 II complex media were transferred into the CELLBAG (final 
culture volume = 6 L) and infected for 2 days under the following infection 
conditions: 22 rpm, 8.5° of rocking angle, 50% O2, air flow rate, 0.25 L/min, and 
27°C. Two days later, a fraction of the cells was harvested for the binding assay 
and the remaining cells were centrifuged at 6,000 × g for 10 min and harvested. 
The cell pellet was washed with 250 ml of Phosphate Buffered Saline without 
calcium chloride and magnesium chloride (PBS(-)) and resuspended with 100 ml 
of PBS(-) containing a protease inhibitor cocktail tablet (Roche). Final 
concentration of protease inhibitors was 2.5 μg/ml pepstatin, 2 μg/ml PMSF, 20 
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μg/ml leupeptin, and 0.5 mM benzamidine. Cells were quick frozen in liquid 
nitrogen and stored at -80°C. 
 
The membrane was prepared from the M2-T4L expressing Sf9 insect cells as 
described previously31. For the preparation of membranes from insect cells, Sf9 
insect cells were centrifuged at 1,500 g for 10 min at 4°C. The pellet was washed 
with PBS(-), then resuspended in 100 ml of hypotonic buffer containing 10 mM 
HEPES at pH 7.5, 20 mM KCl, 10 mM MgCl2, and protease inhibitor cocktail, 
followed by Dounce homogenization to resuspend the membranes. Insect cell 
membranes were centrifuged at 100,000 g for 30 min and the pellets were 
resuspended in 10 mM HEPES at pH 7.5, 10 mM MgCl2, 20 mM KCl, 40% 
glycerol, and snap-frozen in liquid nitrogen and then stored at -80 ºC until use. 
Membrane proteins were quantified using the bicinchoninic acid (BCA) method 
(Pierce) using a BSA standard. 
 
Purification of M2-T4L-QNB 
M2-T4L was expressed in Sf9 cells, solubilized with digitonin/Na-cholate solution, 
and purified by using an affinity column with aminobenztropine (ABT) as a 
ligand33, as described below. The whole procedure was carried out at 4oC.  Sf9 
membrane preparations with 2.1 kg of wet weight and approximately 1.5 μmol of 
[3H]QNB binding sites were solubilized with 1% digitonin/0.35% Na-cholate/10 
mM K-phosphate buffer (pH 7.0) (KPB)/50 mM NaCl/1 mM EDTA/a cocktail of 
protease inhibitors (4 L).   The supernatant was applied to two ABT-columns run 
in parallel (500 ml each), followed by washing with 0.1% digitonin/0.1% Na-
cholate/20 mM KPB/150 mM NaCl (2 L x 2) at a rate of approximately 90 ml/hr.  
M2-T4L was eluted from the ABT columns with 0.5 mM atropine/0.1% 
digitonin/0.1% Na-cholate/20 mM KPB/150mM NaCl in 2 L elution volume for 
each column, and was bound to a column of hydroxyapatite (30 ml), which was 
washed at a rate of 30-50 ml/hr with a series of solutions as follows (1) 0.1% 
digitonin/0.1% Na-cholate/20 mM KPB (100 ml), (2) 5 μM QNB/ 0.1% 
digitonin/0.1% Na-cholate/20 mM KPB (600 ml), (3) 0.35% Na-cholate/20 mM 
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KPB (600 ml), (4) 0.2% decylmaltoside/20 mM KPB (500 ml), (5) 0.2% 
decylmaltoside/150 mM KPB (100 ml), (6) 0.2% decylmaltoside/500 mM KPB (60 
ml).  M2-T4L-QNB was finally eluted with 0.2% decylmaltoside/1 M KPB (50 ml).  
The eluate was concentrated to approximately 1 ml (ca 30 mg protein/ml) with 
Amicon Ultra (MILLIPORE), followed by dialysis against 0.2% decylmaltoside/20 
mM Tris-HCl buffer (pH 7.5) and storage in - 80oC.   The yield was estimated to 
be approximately 50% on the assumption that the recovered protein is pure M2-
T4L. Protein concentration was determined using BCA Protein Assay (PIERCE). 
Since we purified M2-T4L as a complex with QNB we could not estimate the 
[3H]QNB binding activity because the dissociation rate of QNB is too slow. 
However, in preliminary experiments using [3H]QNB or dissociable atropine as 
eluants, we confirmed that the receptor is purified to near homogeneity. The 
purity of M2-T4L was confirmed by SDS-PAGE and gel permeation 
chromatography (Supplementary Fig. 6). All QNB used in purification and 
crystallization was the high affinity enantiomer, R-(–)-3-QNB. 
 
Measurement of ligand binding activity 
Ligand binding activity of wild type M2 and M2-T4L receptors was determined as 
described previously34. Briefly, the receptors solubilized from Sf9 membranes 
were incubated with 0.1 - 4 nM [3H]QNB with or without 1 μM atropine,  or with 2 
nM [3H]QNB with various concentrations of carbamylcholine or atropine in 0.1% 
digitonin/20 mM KPB for 60 min at 30oC (total volume 0.2 ml).  The amount of 
[3H]QNB bound to receptors was assayed by using a small column of Sephadex 
G50 fine (2 ml). The density of [3H]QNB binding sites in particulate fraction of M2-




QNB-bound M2-T4L was concentrated to 20 mg/ml in decyl maltoside buffer in a 
volume of approximately 100 μl. A 10% stock solution of lauryl maltose neopentyl 
glycol detergent (MNG, Anatrace) with 100 mM NaCl and 20 mM HEPES pH 7.5 
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was then added to the protein to a final concentration of 1% (w/v) of MNG 
detergent. The sample was incubated 1 hour on ice, then diluted to 1 ml in 0.1% 
MNG buffer and reconcentrated to 50 mg/ml prior to reconstitution. The final 
volume of protein sample at this concentration was typically 20 – 30 μl. Protein 
was reconstituted in cubic phase by mixing with a 1.5-fold weight excess of a 
10:1 monoolein:cholesterol mix by the twin-syringe method35. Briefly, the protein 
and lipid were mixed by passage through coupled syringes 100 times either by 
hand or using a Gryphon LCP robot (Art Robbins Instruments). The reconstituted 
protein was dispensed using a modified ratchet device (Hamilton) or using the 
Gryphon LCP robot in 40nl drops to either 24-well or 96-well glass sandwich 
plates and overlaid with 0.8 μl precipitant solution. A single crystallization lead 
was initially identified using an in-house screen and then optimized. Crystals for 
data collection were grown in 25 to 35% PEG 300, 100 mM ammonium 
phosphate, 2% 2-Methyl-2,4-pentanediol, 100 mM HEPES pH 7.0 – 7.8. Crystals 
reached full size and were harvested after 3 – 4days at 20°C. Typical crystals 
are shown in supplementary figure 7.  
 
Data collection and processing 
Diffraction data were measured at the Advanced Photon Source beamlines 23 
ID-B and 23 ID-D. Several hundred crystals were screened, and a final data set 
was compiled using diffraction wedges of typically 5 degrees from the 23 most 
strongly diffracting crystals. Data reduction was performed using HKL200036. 
Diffraction quality was very heterogeneous, with some crystals diffracting to 2.3 Å 
while others failed to diffract past 3.5 Å. Among the best crystals, most diffracted 
to 3.0 – 2.5 Å. Severe radiation damage and anisotropic diffraction resulted in 
low completeness in higher resolution shells. We report this structure to an 
overall resolution of 3.0Å. Despite the low completeness in high resolution bins, 
inclusion of these reflections significantly improved map quality. Highest shell 
<I>/<σI> is relatively low, in large part due to anisotropy of the diffraction. The 
final resolution cutoff was chosen on the basis of completeness and <I>/<σI> in 
the spherical highest shell, but analysis of average F/σF values along reciprocal 
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space axes suggests resolution limits (based on F/σF > 3) of 3.5, 2.9, and 2.7 Å 
along a*, b*, and c*, respectively. The real space c axis is normal to the plane of 
the lipid membrane in the crystal. 
 
Structure solution and refinement 
The structure was solved by molecular replacement using Phaser37,38 with the 
structure of the inactive β2 adrenergic receptor and T4 lysozyme used as search 
models (PDB ID: 2RH1). The initial molecular replacement model was further 
fitted by rigid body refinement followed by simulated annealing and restrained 
refinement in Phenix39. Iterative manual rebuilding and refinement steps were 
performed with Coot and phenix.refine, respectively. Figures were prepared with 
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Mutation reduces agonist and antagonist affinity by > 10 fold 
Mutation reduces agonist affinity by > 10 fold
Hydrophobic contacts
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